On July 17, 2018, the Food and Drug Administration (FDA) approved Symtuza, a new combination antiretroviral drug to treat HIV infection in adults:
- who have never taken HIV medicines before, or
- who have a viral load less than 50 copies per mL, have been on a stable treatment regimen for at least 6 months, and have no known substitutions associated with resistance to darunavir or tenofovir.
The 4-drug (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) fixed-dose combination tablet is a complete regimen for the treatment of HIV infection and should not be used with other HIV medicines.
Do you want to learn more about HIV medicines? Check out the AIDSinfo FDA-Approved HIV Medicines fact sheet.